RU2010105646A - Способ регенерации ткани - Google Patents

Способ регенерации ткани Download PDF

Info

Publication number
RU2010105646A
RU2010105646A RU2010105646/10A RU2010105646A RU2010105646A RU 2010105646 A RU2010105646 A RU 2010105646A RU 2010105646/10 A RU2010105646/10 A RU 2010105646/10A RU 2010105646 A RU2010105646 A RU 2010105646A RU 2010105646 A RU2010105646 A RU 2010105646A
Authority
RU
Russia
Prior art keywords
epo
liver
tissue
days
wound
Prior art date
Application number
RU2010105646/10A
Other languages
English (en)
Other versions
RU2542391C2 (ru
Inventor
Аугустинус БАДЕР (DE)
Аугустинус БАДЕР
Original Assignee
Аугустинус БАДЕР (DE)
Аугустинус БАДЕР
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10361813A external-priority patent/DE10361813A1/de
Priority claimed from EP03029961A external-priority patent/EP1550715A1/de
Application filed by Аугустинус БАДЕР (DE), Аугустинус БАДЕР filed Critical Аугустинус БАДЕР (DE)
Publication of RU2010105646A publication Critical patent/RU2010105646A/ru
Application granted granted Critical
Publication of RU2542391C2 publication Critical patent/RU2542391C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)

Abstract

1. Применение эритропоэтина (ЭПО) для производства медикамента для местного использования для ускоренной структурной регенерации кожи при плохо заживающих ранах или ранах от ожоговых повреждений, причем регенерация кожи осуществляется без образования рубцов. ! 2. Применение по п.1, отличающееся тем, что ЭПО вводят после проведения механической санации раневой полости в коагулят крови в ране. ! 3. Способ лечения плохо заживающих ран или ран от ожоговых повреждений, отличающийся тем, что для ускоренной структурной регенерации кожи рану обрабатывают с использованием эритропоэтина (ЭПО), причем регенерация кожи осуществляется без образования рубцов. ! 4. Способ по п.3, отличающийся тем, что ЭПО вводят после проведения механической санации раневой полости в коагулят крови в ране.

Claims (4)

1. Применение эритропоэтина (ЭПО) для производства медикамента для местного использования для ускоренной структурной регенерации кожи при плохо заживающих ранах или ранах от ожоговых повреждений, причем регенерация кожи осуществляется без образования рубцов.
2. Применение по п.1, отличающееся тем, что ЭПО вводят после проведения механической санации раневой полости в коагулят крови в ране.
3. Способ лечения плохо заживающих ран или ран от ожоговых повреждений, отличающийся тем, что для ускоренной структурной регенерации кожи рану обрабатывают с использованием эритропоэтина (ЭПО), причем регенерация кожи осуществляется без образования рубцов.
4. Способ по п.3, отличающийся тем, что ЭПО вводят после проведения механической санации раневой полости в коагулят крови в ране.
RU2010105646/10A 2003-12-30 2004-12-30 Способ регенерации ткани RU2542391C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03029961.4 2003-12-30
DE10361813A DE10361813A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regeneration von Gewebe
DE10361813.9 2003-12-30
EP03029961A EP1550715A1 (de) 2003-12-30 2003-12-30 Verfahren zur Regenation von Gewebe

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2006120458/13A Division RU2392314C2 (ru) 2003-12-30 2004-12-30 Способ регенерации ткани

Publications (2)

Publication Number Publication Date
RU2010105646A true RU2010105646A (ru) 2011-08-27
RU2542391C2 RU2542391C2 (ru) 2015-02-20

Family

ID=34740522

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2006120458/13A RU2392314C2 (ru) 2003-12-30 2004-12-30 Способ регенерации ткани
RU2010105646/10A RU2542391C2 (ru) 2003-12-30 2004-12-30 Способ регенерации ткани

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2006120458/13A RU2392314C2 (ru) 2003-12-30 2004-12-30 Способ регенерации ткани

Country Status (14)

Country Link
US (2) US7910547B2 (ru)
EP (2) EP1699915B1 (ru)
JP (2) JP4903580B2 (ru)
AT (1) ATE469654T1 (ru)
AU (2) AU2004309083B2 (ru)
BR (1) BRPI0418326A (ru)
CA (1) CA2550301A1 (ru)
DE (1) DE502004011252D1 (ru)
DK (2) DK2233150T3 (ru)
ES (2) ES2606068T3 (ru)
PL (2) PL1699915T3 (ru)
PT (1) PT1699915E (ru)
RU (2) RU2392314C2 (ru)
WO (1) WO2005063965A1 (ru)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026480A1 (de) * 2000-05-29 2001-12-13 Augustinus Bader Verfahren zur Herstellung eines empfängerspezifischen Gewebe-Transplantats oder -Implantats
CA2550301A1 (en) * 2003-12-30 2005-07-14 Bionethos Holding Gmbh Tissue regeneration method
JP4982841B2 (ja) * 2005-10-12 2012-07-25 国立大学法人名古屋大学 再生医療骨組成物
US20080107632A1 (en) * 2006-09-06 2008-05-08 Henrich Cheng Fibrin glue composition for repairing nerve damage and methods thereof
JP4696247B2 (ja) * 2006-12-11 2011-06-08 国立大学法人 筑波大学 肝線維化抑制剤
JP5098018B2 (ja) * 2007-03-06 2012-12-12 国立大学法人 筑波大学 肝炎治療剤
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
US20110123481A1 (en) 2007-08-16 2011-05-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
WO2009083203A2 (de) * 2007-12-28 2009-07-09 Heraeus Kulzer Gmbh Topische anwendung und formulierung von erythropoietin für die wundheilung der haut
WO2009089324A1 (en) * 2008-01-08 2009-07-16 Yale University Compositions and methods for promoting patency of vascular grafts
EP2268301B1 (en) * 2008-01-24 2020-02-26 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for bone regeneration
EP2257163A4 (en) * 2008-03-10 2012-01-18 Marfly 2 Lp BONE PASTE COMPOSITION
WO2009121503A2 (de) * 2008-03-31 2009-10-08 Augustinus Bader Verfahren und zusammensetzung zur regeneration von gewebe mit hilfe von stamm- oder knochenmarkzellen
AU2009331840B2 (en) * 2008-12-24 2015-03-12 Augustinus Bader Rapid preparation and use of engineered tissue and scaffolds as individual implants
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
CA2790873A1 (en) * 2010-02-22 2011-08-25 President And Fellows Of Harvard College Methods of generating engineered innervated tissue and uses thereof
MX2012009768A (es) * 2010-02-23 2013-02-27 Sebana Medical Ltd Metodos y composiciones para aumentar la supervivencia del injerto de grasa.
WO2011153512A2 (en) 2010-06-03 2011-12-08 Indiana University Research And Technology Corporation Use of compounds with thrombopoietic activity to promote bone growth and healing
ES2632164T3 (es) 2010-07-06 2017-09-11 Augustinus Bader Aplicación tópica de eritropoyetina para uso en el tratamiento de lesiones de la córnea
WO2012031778A1 (de) 2010-09-12 2012-03-15 Augustinus Bader Verwendung von erythropoietin bei der heilung von wunden oder gewebedefekten ohne narbenbildung
WO2012148200A2 (ko) * 2011-04-26 2012-11-01 아주대학교 산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
US11311367B2 (en) 2012-01-31 2022-04-26 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
JP6258224B2 (ja) * 2012-01-31 2018-01-10 ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ 工学的構造物の神経支配
US9795965B2 (en) 2013-01-03 2017-10-24 Brigham And Women's Hospital, Inc. System and method for a biomimetic fluid processing
RU2522816C1 (ru) * 2013-02-12 2014-07-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Композиция для клеточно-заместительной терапии дефектов мягких тканей
JP6909370B2 (ja) 2014-03-31 2021-07-28 ブリガム・アンド・ウイミンズ・ホスピタル・インコーポレイテッド バイオミメティック流体処理のためのシステム及び方法
JP2016067312A (ja) * 2014-09-30 2016-05-09 株式会社ジーシー 軟骨分化培養液、及び軟骨組織
RU2582948C1 (ru) * 2014-10-23 2016-04-27 Ренат Рашитович Ахмеров Способ волюмизации мягких тканей с помощью термически обработанной тромбоцитарной аутологичной плазмы
US10232048B1 (en) * 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
JP6800984B2 (ja) * 2015-10-05 2020-12-16 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 軟骨傷害の検出及び処置のためのマイクロ並びにナノデバイス
US11541149B2 (en) 2015-12-11 2023-01-03 Research Institute At Nationwide Children's Hospital Systems and methods for optimized patient specific tissue engineering vascular grafts
CN108367007A (zh) * 2015-12-16 2018-08-03 第三共株式会社 用于伤口的治疗剂
US20190015190A1 (en) 2015-12-30 2019-01-17 Wake Forest University Health Sciences Tissue-engineered gut-sphincter complexes and methods of making the same
RU2638796C1 (ru) * 2016-08-05 2017-12-15 Общество с ограниченной ответственностью "Покровский банк стволовых клеток" Способ получения двухкомпонентного препарата для лечения повреждения суставов путем малоинвазивного введения в суставную сумку и препарат, полученный этим способом
JP7167019B2 (ja) 2016-11-10 2022-11-08 エーエスシー・リジェニティー・リミテッド エリスロポエチン由来分子を含む局所適用のための美容用製剤
RU2648869C1 (ru) * 2017-04-03 2018-03-28 Анатолий Владимирович Толстов Способ лечения локальных ожоговых ран II-III А степени
RU2650214C1 (ru) * 2017-04-04 2018-04-11 федеральное государственное бюджетное образовательное учреждение высшего образования "Омский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ОмГМУ Минздрава России) Способ комбинированной остеопластической хирургии околоносовых пазух с использованием фактора роста
RU2666595C1 (ru) * 2017-09-26 2018-09-11 федеральное государственное бюджетное образовательное учреждение высшего образования Кубанский государственный медицинский университет Министерства Здравоохранения Российской Федерации ФГБОУ ВО КубГМУ Минздрава России Гидрогель для коррекции посттрепанационного дефекта черепа
JP7406809B2 (ja) * 2018-03-20 2023-12-28 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 活力のある歯髄の再生
US20210106718A1 (en) * 2019-10-14 2021-04-15 Board Of Regents, The University Of Texas System Mussel inspired nancomposite adhesives for biomedical applications
CN113521049A (zh) * 2021-07-29 2021-10-22 姚雷利 一种妊娠纹脱模修复方法
WO2023168153A1 (en) * 2022-03-03 2023-09-07 Fibrobiologics, Inc. Therapeutic use of fibroblasts to stimulate regeneration and repair of atrophied spleen
WO2023210713A1 (ja) * 2022-04-27 2023-11-02 国立大学法人京都大学 心外膜細胞再生促進剤および心外膜細胞の再生促進方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4954437A (en) 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US6008047A (en) 1993-04-08 1999-12-28 Livercell L.L.C. Cell culturing method and medium
IL110669A (en) 1993-08-17 2008-11-26 Kirin Amgen Inc Erythropoietin analogs
ATE354377T1 (de) * 1993-12-02 2007-03-15 Max Delbrueck Centrum Antitumormittel, enthaltend ein zytostatikum und ein kontrastmittel
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
KR100289201B1 (ko) 1994-02-14 2001-05-02 엘. 데이예를 카렌. 조혈 단백질과 그것의 제조를 위한 재료 및 방법
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US7008634B2 (en) * 1995-03-03 2006-03-07 Massachusetts Institute Of Technology Cell growth substrates with tethered cell growth effector molecules
US5879673A (en) 1996-01-25 1999-03-09 Genentech, Inc. Administration of thrombopoietin on a single day only
US5817343A (en) * 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
RU2115748C1 (ru) * 1996-11-19 1998-07-20 Открытое акционерное общество "АВИСМА титано-магниевый комбинат" Способ переработки отходящих газов магниевого производства
JP2002507907A (ja) 1997-06-27 2002-03-12 バーダー、アウグスチヌス 生合成移植片及びその製造方法
US6165783A (en) * 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
US6776984B1 (en) 1999-08-20 2004-08-17 George R. Schwartz Induced regeneration and repair of damaged neurons and nerve axon myelin
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
WO2001005955A2 (en) * 1999-07-14 2001-01-25 The Board Of Trustees Of The Leland Stanford Junior University Animals comprising human hepatocellular tissue
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
DE10034583A1 (de) 2000-07-14 2002-01-31 Axel Haverich Individuelle Venenklappenprothese
ES2320101T3 (es) * 2000-10-16 2009-05-19 Chugai Seiyaku Kabushiki Kaisha Eritropoyetina conjugada con mono-peg.
ATE505204T1 (de) 2000-12-20 2011-04-15 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
JP2005504010A (ja) 2001-05-17 2005-02-10 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 成長ホルモンおよびｆｏｘｍ１ｂを用いた肝臓疾患および肝臓損傷の処置方法
EP1406680A4 (en) * 2001-06-15 2007-01-10 Johns Hopkins Singapore Pte Lt BIOFUNCTIONAL FIBERS
AU2002343749B2 (en) * 2001-11-16 2007-07-12 Children's Medical Center Corporation Creation of tissue engineered female reproductive organs
ES2422881T3 (es) 2002-06-20 2013-09-16 Augustinus Bader Uso de eritropoyetina para la regeneración de tejido in vivo
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
BR0317752A (pt) * 2002-12-26 2005-11-22 Mountain View Pharmaceuticals Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
DE10303584A1 (de) * 2003-01-30 2004-08-12 Stauss, Robert, Dr. Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten
CA2550301A1 (en) 2003-12-30 2005-07-14 Bionethos Holding Gmbh Tissue regeneration method

Also Published As

Publication number Publication date
JP2012067117A (ja) 2012-04-05
CA2550301A1 (en) 2005-07-14
BRPI0418326A (pt) 2007-05-02
RU2392314C2 (ru) 2010-06-20
US20080031850A1 (en) 2008-02-07
EP2233150A2 (de) 2010-09-29
AU2004309083B2 (en) 2010-11-11
ES2606068T3 (es) 2017-03-17
ES2346226T3 (es) 2010-10-13
ATE469654T1 (de) 2010-06-15
RU2542391C2 (ru) 2015-02-20
JP4903580B2 (ja) 2012-03-28
EP1699915B1 (de) 2010-06-02
PL1699915T3 (pl) 2010-11-30
DK1699915T3 (da) 2010-09-13
WO2005063965A1 (de) 2005-07-14
JP2007517001A (ja) 2007-06-28
PL2233150T3 (pl) 2017-06-30
RU2006120458A (ru) 2008-02-10
EP2233150A3 (de) 2013-01-09
US20110172150A1 (en) 2011-07-14
EP2233150B1 (de) 2016-09-07
US7910547B2 (en) 2011-03-22
EP1699915A1 (de) 2006-09-13
PT1699915E (pt) 2010-08-31
DK2233150T3 (en) 2016-12-12
AU2004309083A1 (en) 2005-07-14
DE502004011252D1 (de) 2010-07-15
AU2011200538B2 (en) 2012-02-23
AU2011200538A1 (en) 2011-03-03

Similar Documents

Publication Publication Date Title
RU2010105646A (ru) Способ регенерации ткани
TWI397411B (zh) 光動力美容步驟及癒合方法
JPH06510453A (ja) 創傷の処理のための組成物及び方法
JP2006510399A (ja) 未分化間葉細胞を用いた組織の治療
US11260077B2 (en) Process for obtaining a sprinkling compound of microvascular endothelial skin cells and mesenchymal stem cells and method of application for tissue regeneration
CN113509590B (zh) 外泌体联合透明质酸的伤口敷料及其制备方法和应用
JP2004522545A (ja) 人工真皮及びその製造方法
KR20040111355A (ko) 미분화 태아 세포를 포함하는 피부 질환 치료용 조성물
NO924323L (no) Nye hybridtransformerende vekstfaktorer
JPH04504569A (ja) 血小板抽出物の塗布による毛の成長促進法
RU2545993C2 (ru) Способ восстановления костных дефектов трубчатых костей критической величины
JP4149897B2 (ja) 気管移植片の調製方法および気管移植片
CN114949358A (zh) 一种用于深部创面修复的复合材料及其制备方法
RU2657202C1 (ru) Способ кожной аутопластики
Ektoras et al. Full-thickness dermal wound regeneration using hypoxia preconditioned blood-derived growth factors: A case series
US6713084B1 (en) Methods for promoting healing of skin resurfacing wounds
CN116036355B (zh) 一种人脂肪脱细胞外基质膜及其制备方法与应用
JP3134079B2 (ja) トロンビンにより凝固した血漿蛋白質により構成された角化細胞培養物のための生物学的支持体、並びに角化細胞培養物を調製し、回収し、治療目的のために移送することにおいて上記支持体を用いる方法
Meagher et al. Skin transplantation in horses.
Sriram A Clinical Study of Efficacy of Modified Vaccum Assisted Dressing in Wound Healing of Open Injuries in Orthopaedics
RU2228763C1 (ru) Способ лечения гнойных ран
Qian et al. New Technology and Tissue Repair and Regeneration (3): Application of Other New Technologies in Tissue Repair and Regeneration
JPH0720873B2 (ja) 創傷治癒剤
Diab et al. Role of Platelet Rich Fibrin (PRF) in Treatment of Post Acne Scars
RU2174395C2 (ru) Способ повышения полноты посттравматической регенерации кожи